Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer

被引:4
作者
Frimpong, Esther [1 ]
Bulusu, Raviteja [1 ]
Okoro, Joy [1 ]
Inkoom, Andriana [1 ]
Ndemazie, Nkafu [1 ,4 ]
Rogers, Sherise [2 ]
Zhu, Xue [1 ]
Han, Bo [3 ]
Agyare, Edward [1 ,5 ]
机构
[1] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL USA
[2] Univ Florida, Dept Med, Div Hematol & Oncol, Coll Med, Gainesville, FL USA
[3] Univ Southern Calif, Keck Sch Med, Dept Surg, Los Angeles, CA USA
[4] Richmond Univ, Med Ctr, Dept Internal Med, Staten Isl, NY USA
[5] 1415 South Martin Luther King Blvd, Tallahassee, FL 32307 USA
基金
美国国家卫生研究院;
关键词
Pyrimidine nucleosides; Pancreatic cancer; Cytotoxicity; Synthesis; 5-FU; Characterization; 5-FLUOROURACIL; GEMCITABINE; MECHANISMS; RESISTANCE; TEGAFUR; THERAPY;
D O I
10.1016/j.ejps.2024.106754
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study proposed modification of 5 -FU by conjugation with an acyl chloride and a 5 -membered heterocyclic ring to improve its in -vitro cytotoxicity and metabolic stability. XYZ-I-71 and XYZ-I-73 were synthesized by introducing a tetrahydrofuran ring on 5-fluorocytosine (a precursor of 5 -FU) and conjugation with octanoyl chloride and lauroyl chloride, respectively. The structure of the synthesized compounds was validated using NMR and micro -elemental analysis. The antiproliferative activity of the analogs was determined against MiaPaCa-2, PANC-1, and BxPC-3 pancreatic cancer cells. The analog's stability in human liver microsomes was quantified by HPLC. We found that the XYZ-I-73 (IC 50 3.6 +/- 0.4 mu M) analog was most effective against MiaPaCa2 cells compared to XYZ-I-71(IC 50 12.3 +/- 1.7 mu M), GemHCl (IC 50 24.2 +/- 1.3 mu M), Irinotecan (IC 50 10.1 +/- 1.5 mu M ) and 5 -FU (IC 50 13.2 +/- 1.1 mu M ) . The antiproliferative effects of this analog in Miapaca-2 cells is evident based on it having a 7-fold,3-fold, and 4 -fold increased cytotoxic effect over Gem-HCl, Irinotecan, and 5 -FU, respectively. On the other hand, XYZ-I-71 exhibited a 2 -fold increased cytotoxic effect over Gem-HCl but a comparable cytotoxic effect to 5 -FU and Irinotecan in MiaPaCa-2 cells. A similar trend of higher XYZ-I-73 inhibition was observed in PANC-1 and BxPC-3 cultures. For 48-h MiaPaCa-2 cell migration studies, XYZ-I-73 (5 mu M) significantly reduced migration (# of migrated cells, 168 +/- 2.9), followed by XYZ-I-71(315 +/- 2.1), Gem-HCl (762 +/- 3.1) and 5 -FU (710 +/- 3.2). PARP absorbance studies demonstrated significant inhibition of PARP expression of XYZ-I73 treated cells compared to 5 -FU, GemHCl, and XYZ-I-71. Further, BAX and p53 expressions were significantly increased in cells treated with XYZ-I-73 compared to 5 -FU, GemHCl, and XYZ-I-71. In -vitro , metabolic stability studies showed that 80 +/- 5.9% of XYZ-I-71 and XYZ-I-73 remained intact after 2 h exposure in liver microsomal solution compared to 5 -FU. The XYZ-I-73 analog demonstrated a remarkable cytotoxic effect and improved invitro metabolic stability over the selected standard drugs and may have potential anticancer activity against pancreatic cancer.
引用
收藏
页数:12
相关论文
共 44 条
[1]   Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer [J].
Adiseshaiah, Pavan P. ;
Crist, Rachael M. ;
Hook, Sara S. ;
McNeil, Scott E. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (12) :750-765
[2]   FN1 encoding fibronectin as a pivotal signaling gene for therapeutic intervention against pancreatic cancer [J].
Ashok, Gayathri ;
Miryala, Sravan Kumar ;
Saju, Megha Treesa ;
Anbarasu, Anand ;
Ramaiah, Sudha .
MOLECULAR GENETICS AND GENOMICS, 2022, 297 (06) :1565-1580
[3]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[4]  
Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1010/j.ejphar.2014.07.041, 10.1016/j.ejphar.2014.07.041]
[5]   The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer [J].
Conroy, Thierry ;
Gavoille, Celine ;
Samalin, Emmanuelle ;
Ychou, Marc ;
Ducreux, Michel .
CURRENT ONCOLOGY REPORTS, 2013, 15 (02) :182-189
[6]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[7]   5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent [J].
Ghafouri-Fard, Soudeh ;
Abak, Atefe ;
Tondro Anamag, Farhad ;
Shoorei, Hamed ;
Fattahi, Faranak ;
Javadinia, Seyed Alireza ;
Basiri, Abbas ;
Taheri, Mohammad .
FRONTIERS IN ONCOLOGY, 2021, 11
[8]   MIA PaCa-2 and PANC-1-pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors [J].
Gradiz, Rui ;
Silva, Henriqueta C. ;
Carvalho, Lina ;
Botelho, Maria Filomena ;
Mota-Pinto, Anabela .
SCIENTIFIC REPORTS, 2016, 6
[9]   Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma [J].
Grossberg, Aaron J. ;
Chu, Linda C. ;
Deig, Christopher R. ;
Fishman, Eliot K. ;
Hwang, William L. ;
Maitra, Anirban ;
Marks, Daniel L. ;
Mehta, Arnav ;
Nabavizadeh, Nima ;
Simeone, Diane M. ;
Weekes, Colin D. ;
Thomas, Charles R., Jr. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (05) :375-403
[10]   Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer [J].
Gusella, M. ;
Crepaldi, G. ;
Barile, C. ;
Bononi, A. ;
Menon, D. ;
Toso, S. ;
Scapoli, D. ;
Stievano, L. ;
Ferrazzi, E. ;
Grigoletto, F. ;
Ferrari, M. ;
Padrini, R. .
ANNALS OF ONCOLOGY, 2006, 17 (11) :1656-1660